NCT05111210 Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
| NCT ID | NCT05111210 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2021-12-14 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2021-12-14 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
Eligibility Criteria
Inclusion Criteria: All patients: * Adults (\>18 years) * Presenting with cutaneous psoriasis * Patients have signed an informed consent * Beneficiary of the health insurance, except for the AME Only for patients of Group 1 * Patients require systemic treatment for psoriasis * Patients are naïve to biological therapies Only for patients of Group 2: * Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision. * Patients are naïve to biological therapies or have received only one biologic, with a "wash-out" period of at least 4 months Non inclusion Criteria: For all : * Patient is minor * Patient is pregnant or breastfeeding * Patient is immunocompromised * Patient is under legal protection, curatorship, guardianship * Patient refuses consent * Patient is unable to comply with study requirements for geographic, social or psychiatric reason. * Beneficiary of the AME Only for patients of Group 1 * Patient has received biologics Only for patients of Group 2 * Patient has a contraindication to the chosen biotherapy * Patient has received biologics within the last 4 months * Patient has been treated with 2 or more biologics * Patient has already received an anti-IL-23 biologic
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05111210 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05111210 currently recruiting?
Yes, NCT05111210 is actively recruiting participants. Contact the research team at lars.rogge@pasteur.fr for enrollment information.
Where is the NCT05111210 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05111210 clinical trial?
NCT05111210 is sponsored by Institut Pasteur. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.